The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .
the long-term trend of higher and higher prices had been broken. According to Morningstar healthcare team leader Damien Conover , a combination of higher prices from the consolidated generics industry, fewer drugs going off patent, and more
Coffina. I'm joined today by Damien Conover , who is the director of our health ..... Damien, thanks for joining me. Damien Conover : Matt, thanks for having me ..... Coffina: Thanks for joining me, Damien . Conover : Matt, thanks for having me
acquiring Cubist. What's our take on the deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment
rest of 2014 might hold for M&A activity in health care, I recently talked with Morningstar health-care analysts Damien Conover , David Krempa, and Michael Waterhouse on May 31. Our discussion has been edited for clarity and length. Question
great competitive advantages. I'm here today with Damien Conover , our director of health-care research, to look ..... health-care space. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: You wrote
the coming years from other companies, so that growth will moderate. But they have a pretty strong pipeline, and Damien Conover , our [TICKER:JNJ] Johnson & Johnson analyst, really sees that their patent losses are pretty manageable
Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .
includes things like Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these
AstraZeneca possibly having a deal. What's our take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure